Arkuda Therapeutics Raises $64 Million Series B Financing To Advance Pipeline Of Programs Targeting Lysosomal Biology To Treat Neurodegenerative Diseases
Amount Raised
$64 Million
Round Type
Series B
WatertownBiotechnologyHealth CareScience And EngineeringDescription
Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal and microglial biology to develop medicines to change the trajectory of neurodegenerative disease, today announced the completion of a $64 million Series B financing. The financing was co-led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from Surveyor Capital (a Citadel company), and Eli Lilly and Company, as well as existing investors Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital.
Quick answer
Arkuda Therapeutics raised $64 Million in a Series B round, dated February 10, 2022. Arkuda Therapeutics is based in Watertown, South Dakota, United States.
- How much did Arkuda Therapeutics raise?
- Arkuda Therapeutics raised $64 Million in a Series B round on February 10, 2022.
- What does Arkuda Therapeutics do?
- Arkuda Therapeutics is a biotechnology company applying insights into lysosomal and microglial biology to drive the development of medicines to change the trajectory of neurodegenerative disease.
- Where is Arkuda Therapeutics based and how big is it?
- Arkuda Therapeutics is based in Watertown, South Dakota, United States.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Arkuda Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Geneos Therapeutics raised $17M (Series A) on March 24, 2022.
- Nucleai raised $33M (Series B) on March 22, 2022.
- Theriva Biologics raised $1.5M (Seed) on March 21, 2022.
- Triumvira Immunologics Inc. raised an undisclosed amount (Series A) on March 17, 2022.
- 2seventy bio raised $170M (Post-IPO Equity) on March 16, 2022.
- MAIA Biotechnology raised $2.4M (Seed) on March 16, 2022.
Who to call at Arkuda Therapeutics, and when
A new round usually means Arkuda Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Arkuda Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Arkuda Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Arkuda Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Arkuda Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansArkuda Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.